Physician-defined Severe Toxicities Occurring During and After Cancer Treatment: Modified Consensus Definitions and Clinical Applicability in the Evaluation of Cancer Treatment

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2023 May 14

PMID 37181427

Authors

Camilla Grud Nielsen

Birthe Lykke Thomsen

Bodil Als-Nielsen

Rachel Conyers

Sima Jeha

Marion K Mateos

Wojciech Mlynarski

Rob Pieters

Mathias Rathe

Kjeld Schmiegelow

Liv Andres-Jensen

Affiliations

Soon will be listed here.

Abstract

Overall survival after cancer is increasing for the majority of cancer types, but survivors can be burdened lifelong by treatment-related severe toxicities. Integration of long-term toxicities in treatment evaluation is not least important for children and young adults with cancers with high survival probability. We present modified consensus definitions of 21 previously published physician-defined Severe Toxicities (STs), each reflecting the most serious long-term treatment-related toxicities and representing an unacceptable price for cure. Applying the Severe Toxicity (ST) concept to real-world data required careful adjustments of the original consensus definitions, translating them into standardized endpoints for evaluating treatment-related outcomes to ensure that (1) the STs can be classified uniformly and prospectively across different cohorts, and (2) the ST definitions allow for valid statistical analyses. The current paper presents the resulting modified consensus definitions of the 21 STs proposed to be included in outcome reporting of cancer treatment.

References

Mlinac M, Feng M . Assessment of Activities of Daily Living, Self-Care, and Independence. Arch Clin Neuropsychol. 2016; 31(6):506-16. DOI: 10.1093/arclin/acw049. View

Mulrooney D, Hyun G, Ness K, Bhakta N, Pui C, Ehrhardt M . The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Haematol. 2019; 6(6):e306-e316. PMC: 6756152. DOI: 10.1016/S2352-3026(19)30050-X. View

Ward E, DeSantis C, Robbins A, Kohler B, Jemal A . Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):83-103. DOI: 10.3322/caac.21219. View

Mueller E, Park E, Kirchhoff A, Kuhlthau K, Nathan P, Perez G . Insurance, chronic health conditions, and utilization of primary and specialty outpatient services: a Childhood Cancer Survivor Study report. J Cancer Surviv. 2018; 12(5):639-646. PMC: 6152932. DOI: 10.1007/s11764-018-0700-1. View

Andersen P, Keiding N . Interpretability and importance of functionals in competing risks and multistate models. Stat Med. 2011; 31(11-12):1074-88. DOI: 10.1002/sim.4385. View

Nathan P, Henderson T, Kirchhoff A, Park E, Yabroff K . Financial Hardship and the Economic Effect of Childhood Cancer Survivorship. J Clin Oncol. 2018; 36(21):2198-2205. DOI: 10.1200/JCO.2017.76.4431. View

Bhakta N, Liu Q, Ness K, Baassiri M, Eissa H, Yeo F . The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017; 390(10112):2569-2582. PMC: 5798235. DOI: 10.1016/S0140-6736(17)31610-0. View

Vetsch J, Wakefield C, Robertson E, Trahair T, Mateos M, Grootenhuis M . Health-related quality of life of survivors of childhood acute lymphoblastic leukemia: a systematic review. Qual Life Res. 2018; 27(6):1431-1443. DOI: 10.1007/s11136-018-1788-5. View

Dixon S, Chen Y, Yasui Y, Pui C, Hunger S, Silverman L . Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2020; 38(29):3418-3429. PMC: 7527155. DOI: 10.1200/JCO.20.00493. View

10.

Magrath I, Steliarova-Foucher E, Epelman S, Ribeiro R, Harif M, Li C . Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013; 14(3):e104-16. DOI: 10.1016/S1470-2045(13)70008-1. View

11.

Jacola L, Partanen M, Lemiere J, Hudson M, Thomas S . Assessment and Monitoring of Neurocognitive Function in Pediatric Cancer. J Clin Oncol. 2021; 39(16):1696-1704. PMC: 8260911. DOI: 10.1200/JCO.20.02444. View

12.

Pui C, Yang J, Hunger S, Pieters R, Schrappe M, Biondi A . Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015; 33(27):2938-48. PMC: 4567699. DOI: 10.1200/JCO.2014.59.1636. View

13.

Andres-Jensen L, Larsen H, Johansen C, Frandsen T, Schmiegelow K, Wahlberg A . Everyday life challenges among adolescent and young adult survivors of childhood acute lymphoblastic leukemia: An in-depth qualitative study. Psychooncology. 2020; 29(10):1630-1637. DOI: 10.1002/pon.5480. View

14.

James S, Ziviani J, Boyd R . A systematic review of activities of daily living measures for children and adolescents with cerebral palsy. Dev Med Child Neurol. 2013; 56(3):233-44. DOI: 10.1111/dmcn.12226. View

15.

Chang W, Katsoulis M, Tan Y, Mueller S, Green K, Lai A . Late effects of cancer in children, teenagers and young adults: Population-based study on the burden of 183 conditions, in-patient and critical care admissions and years of life lost. Lancet Reg Health Eur. 2021; 12:100248. PMC: 8672041. DOI: 10.1016/j.lanepe.2021.100248. View

16.

Kwan P, Arzimanoglou A, Berg A, Brodie M, Hauser W, Mathern G . Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2009; 51(6):1069-77. DOI: 10.1111/j.1528-1167.2009.02397.x. View

17.

Andres-Jensen L, Attarbaschi A, Bardi E, Barzilai-Birenboim S, Bhojwani D, Hagleitner M . Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia. Lancet Haematol. 2021; 8(7):e513-e523. DOI: 10.1016/S2352-3026(21)00136-8. View

18.

Irwin L, Soto E, Chan E, Miller C, Carrington-Forde S, Groves N . Activities of daily living and working memory in pediatric attention-deficit/hyperactivity disorder (ADHD). Child Neuropsychol. 2021; 27(4):468-490. PMC: 8035253. DOI: 10.1080/09297049.2020.1866521. View

19.

Dong H, Robison L, Leisenring W, Martin L, Armstrong G, Yasui Y . Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count. Am J Epidemiol. 2015; 181(7):532-40. PMC: 4371763. DOI: 10.1093/aje/kwu289. View